Vascular Biogenics Company Profile (NASDAQ:VBLT)

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

Vascular Biogenics Ltd. (NASDAQ:VBLT) announced its quarterly earnings data on Monday, August, 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.19) by $0.01. View Vascular Biogenics' Earnings History.

Vascular Biogenics is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for Vascular Biogenics.

4 brokerages have issued 12-month price targets for Vascular Biogenics' shares. Their predictions range from $11.00 to $20.00. On average, they anticipate Vascular Biogenics' stock price to reach $14.75 in the next twelve months. View Analyst Ratings for Vascular Biogenics.

Here are some recent quotes from research analysts about Vascular Biogenics stock:

• 1. According to Zacks Investment Research, "Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. " (10/18/2017)
• 2. Piper Jaffray Companies analysts commented, "At the previous Nov '16 update, the study achieved its primary endpoint of 6-month PFS at therapeutic doses, as well as an intriguing overall survival benefit. However, today's update demonstrates a PFS-6 benefit of 47% vs 25% for therapeutic versus sub-therapeutic doses of VB-111, and confirmed a survival benefit, with mOS at 684 days in the therapeutic cohort. We see these results as meaningful in patients who had progressed on prior therapies including TKi's, and the safety and efficacy profile in this third tumor type reduces risk for VB-111 and the broader platform. That said, we don't expect VBL to pursue a Phase IIb/III trial in thyroid at this time, in favor of focusing on ongoing rGBM and soon-to-be-initiated ovarian cancer studies. In advance of clinical updates from those during 2017, we reiterate OW." (2/21/2017)

Some companies that are related to Vascular Biogenics include BioTime (BTX), Edge Therapeutics (EDGE), Minerva Neurosciences (NERV), ObsEva SA (OBSV), Arrowhead Pharmaceuticals (ARWR), DURECT Corporation (DRRX), Oxford BioMedica plc (OXB), Circassia Pharmaceuticals PLC (CIR), Threshold Pharmaceuticals (MTEM), Ardelyx (ARDX), Stemline Therapeutics (STML), Foamix Pharmaceuticals (FOMX), uniQure N.V. (QURE), Vital Therapies (VTL), Endocyte (ECYT), Chimerix (CMRX), Zymeworks (ZYME) and Faron Pharmaceuticals Oy (FARN).

Vascular Biogenics' management team includes the folowing people:

• Dror Harats M.D., Chief Executive Officer, Founder, Director
• Amos Ron, Chief Financial Officer
• Jacob George M.D., Chief Scientific Officer
• Eyal Breitbart Ph.D., Vice President - Research and Operations
• Erez Feige, Vice President - Business Operations
• Yael Cohen M.D., Vice President - Clinical Development
• Naamit Sher Ph.D., Vice President - Drug Development and Regulatory Affairs
• Ayelet Horn, General Counsel, Company Secretary
• Bennett M. Shapiro M.D., Non-Executive Independent Chairman of the Board
• Ruth Alon, Non-Executive Director, Independent Director

Shares of Vascular Biogenics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Vascular Biogenics stock can currently be purchased for approximately $6.00.